Phathom’s VOQUEZNA Play: Q2 2026 Revenue Rises, Costs Fall, and a Phase 3 Pivot Looms

Financials in Focus

• Revenue: Q2 2026 revenue of $74.3 million, up 88% year over year and 27% versus Q1 2026.
• Prescription momentum: Approximately 1.7 million VOQUEZNA prescriptions filled to date (as of July 17, 2026).
• Q2 prescriptions: About 325,000 VOQUEZNA prescriptions filled in the second quarter.
• Covered prescriptions: Approximately 209,000 filled in Q2, representing roughly 64% of total quarterly prescriptions.
• Operating expenses: $63.1 million in Q2, down 33% versus Q2 2025.
• Profitability: The company reports achieving operating profitability excluding stock-based compensation.
• Guidance: Updated full-year 2026 financial guidance; management signals a more moderate, but still meaningful, revenue path in the second half of 2026.

On the EPS front, the press release does not publish a stand-alone EPS figure or an EPS consensus from analysts. The narrative emphasizes profitability ex-stock-based compensation, but investors will likely seek a clearer sense of net per-share economics as results unfold. The lack of a concrete earnings surprise datapoint leaves room for interpretation as future quarters roll in.

“The second quarter marked an important milestone for Phathom as we delivered strong quarterly revenue growth, achieved operating profitability, excluding stock-based compensation, and continued to build momentum toward realizing the long-term blockbuster potential for VOQUEZNA,” said Steven Basta, President and Chief Executive Officer of Phathom. “Our performance reflects the significant transformation we’ve made over the past year. We have delivered on the pivot to focus our primary call point on gastroenterologists, substantially reduced our expenses, and nearly doubled quarterly revenue for Q2 of 2026 versus Q2 2025. We believe VOQUEZNA has the potential to reach $1 billion in annual revenue through our focus on gastroenterology providers, with an additional $1 billion annual opportunity through expanded engagement in primary care.”

“Phathom is a fundamentally different company than it was a year ago. Our second quarter financial performance demonstrates the continued strengthening of our financial profile as we delivered record quarterly revenue and achieved operating profitability, excluding stock-based compensation, for the first time,” said Sanjeev Narula, Chief Financial and Business Officer of Phathom. “Our more moderate revenue guidance still reflects meaningful growth in the second half of 2026.”

Strategic Updates: From Pivots to Phase 3

In a move that reads like a product-and-pipeline memo, Phathom is initiating a Phase 3 trial to evaluate as-needed dosing of VOQUEZNA in patients with Non-Erosive GERD (NERD). The company frames this as part of a broader trajectory to place VOQUEZNA at the center of GI care, while highlighting an additional growth edge through expanded engagement in primary care.

The near-term narrative remains anchored in VOQUEZNA’s commercial progress and the ongoing intent to tighten the cost base. The company believes the path to a long-term “blockbuster potential” hinges on deep GI adoption and a broader primary-care footprint.

Guidance and Near-Term Outlook

The press release reiterates an updated revenue forecast for 2026 and notes a more moderate growth profile in the second half of the year. While the specific full-year numbers aren’t reiterated here, the emphasis is on sustainability of revenue growth and a continued drive toward profitability on an operating basis, excluding stock-based compensation.

Phathom remains scheduled for a conference call and webcast on July 30, 2026, at 8:00 a.m. EDT to discuss the results and provide additional context for investors.

What This Could Mean for Phathom’s Sector Peers

Phathom’s results spotlight a potentially repeatable template for biotech commercial plays: aggressive focus on a core GI physician audience, aggressive cost discipline, and a direct-to-specialist selling motion that translates prescription volume into top-line growth. If VOQUEZNA uptake continues on pace, the company’s trajectory from revenue growth to profitability—ex- stock-based compensation—could become a blueprint for other early-stage commercial-stage efforts aiming to cross the profitability threshold earlier in the lifecycle.

For sector peers, the narrative underlines a few takeaways: a) the value of a surgical cost structure pivot, b) the importance of a compelling, specialty-driven call point, and c) the optionality of expanding into primary care to unlock a broader revenue runway. Investors will watch whether the revenue forecast upgrade translates into a more confident EPS trajectory in 2027 and how robust VOQUEZNA prescription momentum remains as alternatives and competitors adjust their own go-to-market plans.